Provided by Tiger Trade Technology Pte. Ltd.

Corcept Therapeutics

122.25
+1.200.99%
Post-market: 122.250.00000.00%19:58 EDT
Volume:656.44K
Turnover:80.15M
Market Cap:13.22B
PE:269.48
High:123.44
Open:121.48
Low:120.56
Close:121.05
52wk High:123.44
52wk Low:28.66
Shares:108.10M
Float Shares:96.44M
Volume Ratio:0.88
T/O Rate:0.68%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.4537
EPS(LYR):0.8200
ROE:8.23%
ROA:0.47%
PB:18.72
PE(LYR):149.09

Loading ...

Corcept Therapeutics presents final overall survival data from ROSELLA trial

TIPRANKS
·
Apr 11

Corcept ROSELLA trial shows Lifyorli plus nab-paclitaxel cuts death risk 35%

Reuters
·
Apr 11

Corcept Presents Complete Data From Pivotal Rosella Trial in Sgo Late-Breaker With Simultaneous Publication in the Lancet: Lifyorli™ (Relacorilant) Plus Nab-Paclitaxel Improves Overall Survival in Patients With Platinum-Resistant Ovarian Cancer

THOMSON REUTERS
·
Apr 11

Corcept CDO William Guyer sells 20,000 shares for $819,400

Reuters
·
Apr 09

Corcept Faces Securities Lawsuits As Relacorilant Story Splits On FDA Outcomes

Simply Wall St.
·
Apr 03

Shareholders Sue Corcept Therapeutics Over Cushing’s Syndrome Drug Claims

TIPRANKS
·
Apr 02

MOMENTUM Data Expands Hypercortisolism Opportunity For Corcept Investors

Simply Wall St.
·
Apr 02

Analysts Are Bullish on Top NA Stocks: Ottobock SE & Co. KGaA (OBCKF), Corcept Therapeutics (CORT)

TIPRANKS
·
Mar 30

Corcept Therapeutics presents data from Momentum trial at ACC 2026

TIPRANKS
·
Mar 29

Corcept MOMENTUM trial finds hypercortisolism in 27.3% of resistant hypertension patients

Reuters
·
Mar 29

Corcept Therapeutics Chief Executive Officer Joseph K. Belanoff disposes of 26,198 common shares; value $1,312,000

Reuters
·
Mar 28

Corcept Therapeutics upgraded to Peer Perform from Underperform at Wolfe Research

TIPRANKS
·
Mar 26

Piper Sandler Sticks to Their Buy Rating for Corcept Therapeutics (CORT)

TIPRANKS
·
Mar 26

Corcept Faces Investor Suit Over Relacorilant NDA Disclosure

TIPRANKS
·
Mar 26

Corcept Therapeutics Inc: Wholesale Acquisition Cost of a 28-Day Cycle of Lifyorli Therapy Is $37,900

THOMSON REUTERS
·
Mar 26

BUZZ-U.S. STOCKS ON THE MOVE-ADMA Biologics, Nanobiotix, DraftKings

Reuters
·
Mar 26

Corcept Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Mar 26

FDA Approves Corcept’s Selective Glucocorticoid Receptor Antagonist Lifyorli™ (Relacorilant) Plus Nab-Paclitaxel for Treatment of Patients With Platinum-Resistant Ovarian Cancer

THOMSON REUTERS
·
Mar 26

Corcept Rockets 48% after FDA Lifyorli Approval — What Does This Mean for CORT Stock?

TIPRANKS
·
Mar 26

Corcept Therapeutics price target lowered to $60 from $67 at H.C. Wainwright

TIPRANKS
·
Mar 26